Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hematopoietic Cell Transplantation and TLI for Immunosuppression Withdrawal in Kidney Transplant Recipients
NCT03591302Phase 1Recruiting
- Start
- Feb 2024
- Primary completion
- Oct 2028
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hematopoietic stem cells in kidney transplantation. Primary endpoint: Percentage of patients no longer dependent on immunosuppressive drugs to maintain normal renal function at 5 years. Started Feb 2024; status: recruiting.
02
Drugs
hematopoietic stem cells
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT03591302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591302.